<DOC>
	<DOCNO>NCT01928225</DOCNO>
	<brief_summary>Cervical cancer occur commonly HIV-infected woman South Africa . These woman poor response treatment cervical cancer precursor . This study test whether give quadrivalent vaccine woman prior surgical treatment cervical cancer precursor improve outcome . We hypothesize pre-treatment HPV vaccine result reduce occurrence cervical cancer precursor follow-up .</brief_summary>
	<brief_title>Randomized , Double Blind Trial Quadrivalent HPV Vaccine Improve Responses LEEP Treatment Cervical HSIL</brief_title>
	<detailed_description>This single-center , randomize , double-blinded , placebo-controlled , phase II trial quadrivalent human papillomavirus vaccine ( qHPV ) HIV-infected woman prevent occurrence cervical HSIL LEEP/LLETZ . Participants undergo colposcopy direct biopsy , cervical cytology , store HPV test prior vaccination . Participants randomize quadrivalent vaccine saline placebo give entry , week 4 , week 26 . Women LEEP treatment week 4 . Participants see follow-up cervical cytology , colposcopy direct biopsy week 26 52 , store HPV specimen . Treatment assignment unblinded study follow-up complete last study participant . Women age 45 less randomize placebo offer open label HPV vaccine study concluded..</detailed_description>
	<mesh_term>Squamous Intraepithelial Lesions Cervix</mesh_term>
	<mesh_term>Uterine Cervical Dysplasia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . HIV infection 2 . Women age ≥ 18 year . 3 . Cervical HSIL biopsy ( i.e . CIN2 and/or CIN3 ) 4 . For participant reproductive potential , negative serum urine pregnancy test 5 . All study participant must agree participate conception process ( e.g. , active attempt become pregnant vitro fertilization ) study participation ( time study entry week 52 ) . 1 . History current biopsy diagnosis invasive microinvasive cervical , vaginal , vulvar , anal oropharyngeal cancer 2 . Prior hysterectomy 3 . Cervical cryotherapy LEEP/LEETZ within one year entry . 4 . Cervical , vulvar , vaginal lesion suspicious cancer , unless biopsy show invasive cancer 5 . Prior receipt one dose HPV vaccine . 6 . Receipt anticoagulant aspirin nonsteroidal antiinflammatory drug ( NSAIDS ) within 14 day prior entry . 7 . Known allergy/sensitivity hypersensitivity yeast component study product formulation ( see section 5.2 list component ) . 8 . Hemophilia bleeding diatheses . 9 . Use systemic antineoplastic immunomodulatory treatment , systemic corticosteroid , inhaled corticosteroid prednisone ≤ 10 mg ( equivalent ) , investigational vaccine , interleukin , interferon , growth factor , intravenous immunoglobulin ( IVIG ) within 45 day prior study entry . 10 . Breastfeeding 11 . Less 3 month postpartum</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>HSIL</keyword>
	<keyword>CIN</keyword>
	<keyword>HPV</keyword>
	<keyword>HPV vaccination</keyword>
	<keyword>gardasil</keyword>
	<keyword>HIV</keyword>
	<keyword>cervical dysplasia</keyword>
	<keyword>LEEP</keyword>
	<keyword>cervical cancer</keyword>
</DOC>